Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven ...
Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with ...
Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer baseAdvance SeaStar Medical’s ...
XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...
New research reveals that aging immune cells can become locked in a self-sustaining inflammatory state, worsening the body’s ...
The field of sepsis research has advanced significantly in recent years, particularly regarding the interplay between immune responses and multiple forms of ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Professors Yao Yongming and Du Xiaohui, leading a research group at the Chinese PLA General Hospital, have published groundbreaking findings demonstrating that CD4+ T lymphocytes undergo PANoptosis ...
Each year, around 15 million babies are born prematurely, with nearly one million dying soon after due to complications. Maternal mortality remains high, particularly in low-resource settings. This ...
A simple, scalable hospital program improved hand hygiene, sped up sepsis treatment, and sharply reduced severe infection outcomes, showing how small, coordinated changes can save mothers’ lives even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback